What is mPharma?
Founded in 2013 and headquartered in Ghana, mPharma operates as a sophisticated health-tech startup dedicated to establishing a comprehensive network of community pharmacies. Moving beyond traditional retail models, the company functions as a decentralized network of mini-hospitals. These facilities provide essential medical consultations, diagnostic services, and telehealth integration, effectively bridging the gap in healthcare accessibility and affordability. By optimizing the supply chain and integrating digital health solutions, mPharma is positioning itself as the primary healthcare provider for millions, addressing systemic inefficiencies in the African medical market through a scalable, tech-enabled platform.
How much funding has mPharma raised?
mPharma has raised a total of $68.3M across 5 funding rounds:
Series A
$6.6M
Series B
$9.7M
Series C
$17M
Series D
$30M
Debt
$5M
Series A (2017): $6.6M with participation from 4DX Ventures, Golden Palm Investments, and Social Capital
Series B (2019): $9.7M led by Cem Garih, Novastar Ventures, and Unbound
Series C (2020): $17M supported by CDC Group Plc
Series D (2022): $30M featuring Unbound, Lux Capital, and JAM Fund
Debt (2022): $5M backed by Citi
Key Investors in mPharma
Social Capital
Social Capital is a venture firm focused on solving complex global problems by empowering entrepreneurs who aim to improve lives through technology and innovation.
Golden Palm Investments
Golden Palm Investments Corporation is an investment holding firm focused on high-growth technology opportunities across fundamental industries in Africa.
Novastar Ventures
Novastar is an investment manager dedicated to fueling an entrepreneurial revolution in Africa by partnering with initiatives that benefit both people and the planet.
What's next for mPharma?
With the infusion of $30M, mPharma is well-positioned to accelerate its enterprise-level expansion. The strategic focus will likely shift toward deepening its footprint in existing markets while scaling its telehealth and diagnostic capabilities to meet rising demand. As the company matures, the integration of advanced data analytics and supply chain automation will be paramount in maintaining its competitive edge. Investors are closely monitoring how this capital will be deployed to further integrate the company into the broader African healthcare ecosystem, potentially setting the stage for future market consolidation or public market entry.
See full mPharma company page
